Ortho’s VITROS® SARS-CoV-2 Antigen Test for Accurate, Mass-Scale COVID-19 Testing is the First Widely-Available, High-Volume Test to Receive FDA Emergency Use Authorization
- Ortho Clinical Diagnostics
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced that its VITROS® SARS-CoV-2 Antigen Test, designed to detect active infection, has become the first high-volume COVID-19 antigen test to receive Food and Drug Administration (FDA) Emergency Use Authorization (EUA). U.S. distribution of the test commenced in November 2020 under an FDA Emergency Use Notification (EUN); the test was also granted CE Mark in November 2020. Read more…
Related Reading
News / COVID-19 / Global & Trade
AdvaMed Statement on USITC report, “COVID-19 Diagnostics and Therapeutics, Supply, Demand, and TRIPS Agreement Flexibilities”
October 20, 2023
The United States International Trade Commission (USITC) released its highly anticipated report,“COVID-19 Diagnostics and Therapeutics, Supply, Demand, and TRIPS Agreement Flexibilities” on October 17. Evidence presented in the 496-page report supports AdvaMed’s position that there is no justification for the World Trade Organization (WTO) to waive intellectual property protection for products used to treat or diagnose COVID-19.
News / Coverage & Payment / COVID-19 / Regulatory Affairs
Medtech POV Podcast: Titan Medical’s Cary Vance Talks Robotic Innovation in Medtech, the Importance of MDUFA V, and Addressing Supply Chain Issues
December 6, 2022
Cary Vance, President and CEO of Titan Medical, joined AdvaMed’s Scott Whitaker on the Medtech POV podcast to share his experience leading a small medical device company through the regulatory process as they transition from design to manufacturing.
Resource / COVID-19 / Global & Trade
The Global Medtech Industry: Rewiring Medtech in a Post-Pandemic World
October 20, 2022
This white paper from IQVIA – an associate member of AdvaMed – discusses how global markets and specific therapeutic areas are poised for growth over the next decade.
Resource / COVID-19 / Diagnostics
AdvaMed COVID Testing Supply Registry – Weekly Report
September 24, 2022
This report outlines a key data-driven summary of the U.S. COVID testing supply.
Blog / COVID-19 / Digital Health / Global & Trade / Supply Chain
ResMed CEO Mick Farrell on Leadership, Learning from Experience, and Giving Back
July 27, 2022
Mick Farrell, CEO of ResMed, joined Scott Whitaker on the Medtech POV podcast to explain what motivates him to serve patients and his community.
News / COVID-19 / Global & Trade / Government & Legislative Affairs / Supply Chain
New Episode of Medtech POV Podcast: ResMed CEO Discusses Scaling Up Ventilator Production, Navigating Semiconductor Chips Shortages, to Put Patients First
July 26, 2022
Mick Farrell, ResMed CEO and member of the AdvaMed board of directors, joined AdvaMed’s Scott Whitaker on the Medtech POV podcast to discuss how an agile company with skilled staff and a clear mission can pivot sharply as the market demands, from scaling up ventilator production at the outset of the COVID-19 pandemic to informing semiconductor chips manufacturers of their product’s critical importance to the medical technology industry.
Resource / COVID-19 / Diagnostics
AdvaMedDx COVID Testing Supply Retrospective Report
June 10, 2022
This report examines cumulative data from the first two years of the COVID Test Registry to demonstrate the mobilization of the diagnostics industry over the course of the pandemic.
News / COVID-19 / Government & Legislative Affairs
AdvaMed Calls for Renewed Effort to Sustain and Strengthen COVID Test Manufacturing
March 16, 2022
Today, AdvaMed President and CEO Scott Whitaker issued a statement following the White House’s announcement that the federal government’s COVID-19 response would be reduced in the coming weeks without additional funding from Congress: